Compare Ascendis Pharma A/S (ASND) vs Kaltura Inc (KLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Kaltura Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Kaltura Inc trades at $1.25 (market cap $191.73M). The key difference: Ascendis Pharma A/S is far larger — about 92.5× Kaltura Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| ASND | KLTR | |
|---|---|---|
Market Cap | $17.74B | $191.73M |
Sector | Health | Technology |
52-Week High | $277.18 | $1.97 |
52-Week Low | $163.32 | $1.08 |
Enterprise Value | $18.11B | $174.45M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Kaltura (KLTR) trades at $1.28, up 0.79% with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent industry recognitions highlight Kaltura's leadership in AI-powered digital engagement platforms, though negative ROE and high P/B ratio of 41.29 indicate valuation concerns.
While Kaltura demonstrates operational improvement and strong industry positioning, the stock faces headwinds from persistent losses and bearish technical signals. The mixed analyst sentiment (44% buy, 33% hold, 22% sell) reflects uncertainty about profitability timeline. Investment appeal hinges on the company's ability to convert AI innovation into sustainable earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
